The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $455.17

Today's change-0.53 -0.12%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.
 

Regeneron Pharmaceuticals Inc

Nasdaq: REGN
Last

(U.S.) $455.17

Today's change-0.53 -0.12%
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.

Regeneron Pharmaceuticals Inc down (U.S.)$0.53

Regeneron Pharmaceuticals Inc closed lower Friday, dropping (U.S.)$0.53 or 0.12% to (U.S.)$455.17. Over the last five days, shares have gained 1.15% and are currently 1.99% off of the 52-week high. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $456.70
  • Previous close(U.S.) $455.70
  • High(U.S.) $459.25
  • Low(U.S.) $453.35
  • Bid / Ask(U.S.) $455.25 / (U.S.) $500.00
  • YTD % change+23.99%
  • Volume475,520
  • Average volume (10-day)828,095
  • Average volume (1-month)923,800
  • Average volume (3-month)913,935
  • 52-week range(U.S.) $325.35 to (U.S.) $464.40
  • Beta1.52
  • Trailing P/E54.76×
  • P/E 1 year forward35.95×
  • Forward PEG1.88×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $8.31
Updated May 26 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue1,3191,2271,2201,213
Total other revenue--------
Total revenue1,3191,2271,2201,213
Gross profit1,2351,1521,1761,144
Total cost of revenue84754469
Total operating expense888880857921
Selling / general / administrative297326270292
Research & development507479543560
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income431347363292
Interest income (expense), net non-operating-8------
Gain (loss) on sale of assets--------
Other--------
Income before tax432342366292
Income after tax249253265196
Income tax, total1838810196
Net income249253265196
Total adjustments to net income--------
Net income before extra. items249253265196
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items249253265196
Inc. avail. to common incl. extra. items249253265196
Diluted net income249253265196
Dilution adjustment--000
Diluted weighted average shares115116116116
Diluted EPS excluding extraordinary itemsvalue per share2.162.192.271.69
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share2.162.192.271.69